Time filter

Source Type

PubMed | National Cancer Center Research Institute, Vall dHebron Institute of Oncology VHIO Hospital Vall dHebron and Prediction Institute
Type: Journal Article | Journal: Oncotarget | Year: 2016

Small cell lung cancer (SCLC) is the most aggressive type of lung cancer with high mortality. One of the MYC family genes, MYC, MYCL or MYCN, is amplified in ~20% of the SCLCs; therefore, MYC proteins are potential therapeutic targets in SCLC patients. We investigated the therapeutic impact of Omomyc, a MYC dominant negative, in a panel of SCLC cell lines. Strikingly, Omomyc suppressed the growth of all tested cell lines by inducing cell cycle arrest and/or apoptosis. Induction of G1 arrest by Omomyc was found to be dependent on the activation of CDKN1A, in part, through the TP73 pathway. Our results strongly indicate that SCLC cells carrying amplification of MYC, MYCL or MYCN are addicted to MYC function, suggesting that MYC targeting would be an efficient therapeutic option for SCLC patients.

Loading Vall dHebron Institute of Oncology VHIO Hospital Vall dHebron collaborators
Loading Vall dHebron Institute of Oncology VHIO Hospital Vall dHebron collaborators